Disturbed Transcription of TLRs’ Negative Regulators and Cytokines Secretion among TLR4- and 9-Activated PBMCs of Agammaglobulinemic Patients

References

• Ataeinia B, Montazeri A, Tavakol M, et al. (2017). Measurement of health-related quality of life in primary antibody-deficient patients. Immunol Invest, 46, 329–340. doi:10.1080/08820139.2016.1258710
   PubMed Web of Science ®Google Scholar
• Bao Y, Zheng J, Han C, et al. (2012). Tyrosine kinase BTK is required for NK cell activation. J Biol Chem, 287, 23769–23778. doi:10.1074/jbc.M112.372425
   PubMed Web of Science ®Google Scholar
• Bayry J, Dasgupta S, Misra N, et al. (2006). Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms. Int Immunopharmacol, 6, 528–534. doi:10.1016/j.intimp.2005.11.013
   PubMed Web of Science ®Google Scholar
• Bruton OC. (1952). Agammaglobulinemia. Pediatrics, 9, 722–728.
   PubMed Web of Science ®Google Scholar
• Campos-Sanchez E, Martinez-Cano J, Del Pino Molina L, et al. (2019). Epigenetic deregulation in human primary immunodeficiencies. Trends Immunol, 40, 49–65. doi:10.1016/j.it.2018.11.005
   PubMed Web of Science ®Google Scholar
• Cavaliere FM, Prezzo A, Bilotta C, et al. (2017). The lack of BTK does not impair monocytes and polymorphonuclear cells functions in x-linked agammaglobulinemia under treatment with intravenous immunoglobulin replacement. PLoS One, 12, e0175961. doi:10.1371/journal.pone.0175961
   PubMed Web of Science ®Google Scholar
• de Weers M, Verschuren MC, Kraakman ME, et al. (1993). The Bruton‘s tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages. Eur J Immunol, 23, 3109–3114. doi:10.1002/eji.1830231210
   PubMed Web of Science ®Google Scholar
• Doyle SL, Jefferies CA, Feighery C, et al. (2007). Signaling by toll-like receptors 8 and 9 requires Bruton‘s tyrosine kinase. J Biol Chem, 282(51), 36953–36960. doi:10.1074/jbc.M707682200
   PubMed Web of Science ®Google Scholar
• Doyle SL, Jefferies CA, O‘Neill LA. (2005). Bruton‘s tyrosine kinase is involved in p65-mediated transactivation and phosphorylation of p65 on serine 536 during NFkappaB activation by lipopolysaccharide. J Biol Chem, 280, 23496–23501. doi:10.1074/jbc.C500053200
   PubMed Web of Science ®Google Scholar
• Fearns C, Pan Q, Mathison JC, et al. (2006). Triad3a regulates ubiquitination and proteasomal degradation of RIP1 following disruption of HSP90 binding. J Biol Chem, 281, 34592–34600. doi:10.1074/jbc.M604019200
   PubMed Web of Science ®Google Scholar
• Fiedler K, Sindrilaru A, Terszowski G, et al. (2011). Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of x-linked agammaglobulinemia. Blood, 117, 1329–1339. doi:10.1182/blood-2010-04-281170
   PubMed Web of Science ®Google Scholar
• Gonzalez-Serrano ME, Estrada-Garcia I, Mogica-Martinez D, et al. (2012). Increased pro-inflammatory cytokine production after lipopolysaccharide stimulation in patients with x-linked agammaglobulinemia. J Clin Immunol, 32, 967–974. doi:10.1007/s10875-012-9706-z
   PubMed Web of Science ®Google Scholar
• Hasan M, Lopez-Herrera G, Blomberg KE, et al. (2008). Defective toll-like receptor 9-mediated cytokine production in B cells from Bruton‘s tyrosine kinase-deficient mice. Immunology, 123, 239–249. doi:10.1111/j.1365-2567.2007.02693.x
   PubMed Web of Science ®Google Scholar
• Hernandez-Trujillo VP, Scalchunes C, Cunningham-Rundles C, et al. (2014). Autoimmunity and inflammation in x-linked agammaglobulinemia. J Clin Immunol, 34(6), 627–632. doi:10.1007/s10875-014-0056-x
   PubMed Web of Science ®Google Scholar
• Horwood NJ, Mahon T, McDaid JP, et al. (2003). Bruton‘s tyrosine kinase is required for lipopolysaccharide-induced tumor necrosis factor alpha production. J Exp Med, 197(12), 1603–1611. doi:10.1084/jem.20021845
   PubMed Web of Science ®Google Scholar
• Horwood NJ, Page TH, McDaid JP, et al. (2006). Bruton‘s tyrosine kinase is required for TLR2 and TLR4-induced TNF, but not IL-6, production. J Immunol, 176(6), 3635–3641.
   PubMed Web of Science ®Google Scholar
• Jefferies CA, Doyle S, Brunner C, et al. (2003). Bruton‘s tyrosine kinase is a toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by toll-like receptor 4. J Biol Chem, 278(28), 26258–26264. doi:10.1074/jbc.M301484200
   PubMed Web of Science ®Google Scholar
• Jyothi S, Lissauer S, Welch S, et al. (2013). Immune deficiencies in children: an overview. Postgrad Med J, 89(1058), 698–708. doi:10.1136/postgradmedj-2012-302278rep
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Kitaura J, Hata D, et al. (1999). Functions of Bruton‘s tyrosine kinase in mast and B cells. J Leukoc Biol, 65(3), 286–290.
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Hernandez LD, Galan JE, et al. (2002). IRAK-M is a negative regulator of toll-like receptor signaling. Cell, 110(2), 191–202.
   PubMed Web of Science ®Google Scholar
• Koprulu AD, Ellmeier W. (2009). The role of TEC family kinases in mononuclear phagocytes. Crit Rev Immunol, 29(4), 317–333
   PubMed Web of Science ®Google Scholar
• Lee KG, Xu S, Wong ET, et al. (2008). Bruton‘s tyrosine kinase separately regulates NFkappaB p65rela activation and cytokine interleukin (IL)-10/il-12 production in TLR9-stimulated b cells. J Biol Chem, 283(17), 11189–11198. doi:10.1074/jbc.M708516200
   PubMed Web of Science ®Google Scholar
• Lopez-Herrera G, Vargas-Hernandez A, Gonzalez-Serrano ME, et al. (2014). Bruton‘s tyrosine kinase – an integral protein of b cell development that also has an essential role in the innate immune system. J Leukoc Biol, 95(2), 243–250. doi:10.1189/jlb.0513307
   PubMed Web of Science ®Google Scholar
• Lougaris V, Baronio M, Vitali M, et al. (2014). Bruton tyrosine kinase mediates TLR9-dependent human dendritic cell activation. J Allergy Clin Immunol, 133, 1644–50.e4. doi:10.1016/j.jaci.2013.12.1085
   PubMed Web of Science ®Google Scholar
• Maglione PJ, Simchoni N, Cunningham-Rundles C. (2015). Toll-like receptor signaling in primary immune deficiencies. Ann N Y Acad Sci, 1356, 1–21. doi:10.1111/nyas.12763
   PubMed Web of Science ®Google Scholar
• Mallette FA, Calabrese V, Ilangumaran S, et al. (2010). Socs1, a novel interaction partner of p53 controlling oncogene-induced senescence. Aging (Albany NY), 2, 445–452. doi:10.18632/aging.100163
   PubMedGoogle Scholar
• Mangla A, Khare A, Vineeth V, et al. (2004). Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses. Blood, 104, 1191–1197. doi:10.1182/blood-2004-01-0207
   PubMed Web of Science ®Google Scholar
• Mansell A, Smith R, Doyle SL, et al. (2006). Suppressor of cytokine signaling 1 negatively regulates toll-like receptor signaling by mediating mal degradation. Nat Immunol, 7, 148–155. doi:10.1038/ni1299
   PubMed Web of Science ®Google Scholar
• Marron TU, Martinez-Gallo M, Yu JE, et al. (2012). Toll-like receptor 4-, 7-, and 8-activated myeloid cells from patients with x-linked agammaglobulinemia produce enhanced inflammatory cytokines. J Allergy Clin Immunol, 129, 184–90.e1–4. doi:10.1016/j.jaci.2011.10.009
   PubMed Web of Science ®Google Scholar
• Marron TU, Rohr K, Martinez-Gallo M, et al. (2010). TLR signaling and effector functions are intact in XLA neutrophils. Clin Immunol, 137, 74–80. doi:10.1016/j.clim.2010.06.011
   PubMed Web of Science ®Google Scholar
• Murakami K, Suzuki C, Kobayashi F, et al. (2012). Intravenous immunoglobulin preparation attenuates LPS-induced production of pro-inflammatory cytokines in human monocytic cells by modulating TLR4-mediated signaling pathways. Naunyn Schmiedebergs Arch Pharmacol, 385, 891–898. doi:10.1007/s00210-012-0765-8
   PubMed Web of Science ®Google Scholar
• Nakagawa R, Naka T, Tsutsui H, et al. (2002). Socs-1 participates in negative regulation of LPS responses. Immunity, 17, 677–687.
   PubMed Web of Science ®Google Scholar
• Richard A, Corvol JC, Debs R, et al. (2016). Transcriptome analysis of peripheral blood in chronic inflammatory demyelinating polyradiculoneuropathy patients identifies TNFR1 and TLR pathways in the IVIG response. Medicine (Baltimore), 95. doi:10.1097/md.0000000000003370
   Web of Science ®Google Scholar
• Richardson AM, Moyer AM, Hasadsri L, et al. (2018). Diagnostic tools for inborn errors of human immunity (primary immunodeficiencies and immune dysregulatory diseases). Curr Allergy Asthma Rep, 18(3), 19. doi:10.1007/s11882-018-0770-1
   PubMed Web of Science ®Google Scholar
• Sanaei R, Rezaei N, Aghamohammadi A, et al. (2018). Evaluation of the TLR negative regulatory network in CVID patients. Genes Immun. doi:10.1038/s41435-018-0022-3
   PubMed Web of Science ®Google Scholar
• Schmidt NW, Thieu VT, Mann BA, et al. (2006). Bruton‘s tyrosine kinase is required for TLR-induced IL-10 production. J Immunol, 177(10), 7203–7210.
   PubMed Web of Science ®Google Scholar
• Schwab I, Nimmerjahn F. (2013). Intravenous immunoglobulin therapy. How does IgG modulate the immune system? Nat Rev Immunol, 13, 176–189. doi:10.1038/nri3401
   PubMed Web of Science ®Google Scholar
• Sharma RK, Sehgal S, Sachdeva N, et al. (2019). Direct engagement of TLR9 ligand with t helper cells leads to cell proliferation & up-regulation of cytokines. Immunol Invest, 48, 79–95. doi:10.1080/08820139.2018.1515223
   PubMed Web of Science ®Google Scholar
• Shillitoe B, Gennery A. (2017). X-linked agammaglobulinaemia: outcomes in the modern era. Clin Immunol, 183, 54–62. doi:10.1016/j.clim.2017.07.008
   PubMed Web of Science ®Google Scholar
• Teocchi MA, Domingues Ramalho V, Abramczuk BM, et al. (2015). BTK mutations selectively regulate BTK expression and upregulate monocyte XBP1 MRNA in XLA patients. Immun Inflamm Dis, 3, 171–181. doi:10.1002/iid3.57
   PubMed Web of Science ®Google Scholar
• Tha-In T, Bayry J, Metselaar HJ, et al. (2008). Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol, 29, 608–615. doi:10.1016/j.it.2008.08.004
   PubMed Web of Science ®Google Scholar
• Uckun FM, Qazi S. (2010). Bruton‘s tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity. Expert Opin Ther Pat, 20, 1457–1470. doi:10.1517/13543776.2010.517750
   PubMed Web of Science ®Google Scholar
• Verstrepen L, Verhelst K, van Loo G, et al. (2010). Expression, biological activities and mechanisms of action of a20 (TNFAIP3). Biochem Pharmacol, 80, 2009–2020. doi:10.1016/j.bcp.2010.06.044
   PubMed Web of Science ®Google Scholar
• Vidya MK, Kumar VG, Sejian V, et al. (2018). Toll-like receptors: significance, ligands, signaling pathways, and functions in mammals. Int Rev Immunol, 37, 20–36. doi:10.1080/08830185.2017.1380200
   PubMed Web of Science ®Google Scholar
• Wang J, Lau KY, Jung J, et al. (2014). Bruton‘s tyrosine kinase regulates TLR9 but not TLR7 signaling in human plasmacytoid dendritic cells. Eur J Immunol, 44, 1130–1136. doi:10.1002/eji.201344030
   PubMed Web of Science ®Google Scholar
• Weber ANR, Bittner Z, Liu X, et al. (2017). Bruton‘s tyrosine kinase: an emerging key player in innate immunity. Front Immunol, 8, 1454. doi:10.3389/fimmu.2017.01454
   PubMed Web of Science ®Google Scholar